8-K: ModivCare Reports Mixed Q4 and Full Year 2024 Results; Appoints New Board Members

ModivCare's Q4 2024 results show consistent service revenue year-over-year but a widened net loss, while the full year saw a slight revenue increase but a significant net loss, alongside the appointment of two new board members.

Summary

• ModivCare reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Service revenue for Q4 2024 remained consistent at $702.8 million compared to Q4 2023.
• The company experienced a net loss of $23.5 million, or negative $1.64 per diluted common share, in Q4 2024.
• Adjusted EBITDA for Q4 2024 was $40.4 million, with adjusted EPS at $0.19 per diluted common share.
• Net cash provided by operating activities in Q4 2024 was $30.0 million.
• For the full year 2024, service revenue increased by 1.3% to $2,787.6 million.
• The net loss for the full year was $201.3 million, or negative $14.14 per diluted common share.
• Adjusted EBITDA for the full year was $161.1 million, with adjusted EPS at $0.79 per diluted common share.
• Net cash used in operating activities for the full year was $6.4 million.
• The company amended its Credit Agreement to obtain financial covenant relief through Q2 2025, including a $75.0 million incremental term loan facility.
• Alec Cunningham and David Mounts Gonzales were appointed to the board of directors, effective March 7, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there's a slight revenue increase, the significant net loss and challenges in the industry temper any positive outlook. The new board appointments are a positive sign, but the financial results are concerning.

Positives

• Service revenue remained consistent in Q4 2024 compared to the previous year.
• Full year service revenue saw a slight increase of 1.3%.
• The company secured financial covenant relief and a $75.0 million term loan facility.
• Two new independent directors, Alec Cunningham and David Mounts Gonzales, were appointed to the board, bringing expertise in healthcare, technology, and AI.

Negatives

• The net loss significantly increased in Q4 2024 compared to Q4 2023.
• The company experienced a substantial net loss for the full year 2024.
• Adjusted EBITDA was lower in 2024 primarily due to lower gross margin across each of the segments as a result of increased service expense across each of the segments.
• Net cash used in operating activities for the full year was $6.4 million.

Risks

• The company faces risks related to government and private insurance program funding reductions.
• There are concerns about the implementation of alternative payment models.
• The company is exposed to risks related to cost containment initiatives by payors.
• Weakening economic conditions, including inflationary pressures and labor shortages, pose a risk.
• The company faces risks related to potential failures to comply with data interoperability and information blocking rules.
• The company faces risks related to potential loss of Medicaid coverage by Medicaid beneficiaries as a result of any state Medicaid eligibility determination processes.
• The company's existing debt agreements contain restrictions, financial covenants and cross-default provisions that limit flexibility in operating the business.
• The company has substantial doubt about its ability to meet its obligations as they come due within one year from the date of issuance of the financial statements for fiscal year 2024.

Future Outlook

The company expects working capital to normalize in 2025 as utilization levels stabilize and key clients transition to a fee-for-service contract structure, positioning them to drive long-term shareholder value.

Management Comments

• '2024 proved to be a challenging year in the dynamic and complex markets we serve,' stated L. Heath Sampson, President and CEO.
• He noted the industry faced significant disruption from Medicaid redetermination, surging healthcare utilization, and lower Medicare Advantage reimbursements.
• Looking ahead, the company is positioned in 2025, having a strengthened balance sheet, to drive long-term shareholder value while maintaining commitment to high-quality service.

Industry Context

The announcement highlights the challenges faced by healthcare service companies due to Medicaid redetermination, increased healthcare utilization, and lower Medicare Advantage reimbursements, reflecting broader industry pressures.

Comparison to Industry Standards

• It's difficult to provide a direct comparison to industry standards without specific guidance or benchmarks provided in the document.
• However, companies like Aetna (CVS Health) and WellCare Health Plans are mentioned in the context of Alec Cunningham's experience, suggesting they are relevant comparables in the managed care space.
• Inmar Intelligence, where David Mounts Gonzales served as CEO, is a comparable company in the data-driven commerce and analytics platform industry.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the net losses and lower adjusted EBITDA.
• Employees may experience uncertainty due to restructuring and cost-reduction efforts.
• Customers may be affected by changes in service delivery and contract structures.
• Suppliers may face pressure due to cost containment initiatives.
• Creditors are impacted by the amendment to the Credit Agreement and the issuance of additional debt.

Next Steps

• Modivcare will hold a conference call on March 6, 2025, to discuss its financial results.
• The company is working with its lenders to identify the remaining new Board candidate.

Key Dates

Keywords

ModivCare, financial results, board of directors, NEMT, PCS, monitoring, healthcare, EBITDA, revenue, net loss